PortfoliosLab logoPortfoliosLab logo
CURE.AX vs. TECH.AX
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CURE.AX vs. TECH.AX - Performance Comparison

The chart below illustrates the hypothetical performance of a A$10,000 investment in Global X S&P Biotech ETF (CURE.AX) and Global X Morningstar Global Technology ETF (TECH.AX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CURE.AX achieves a 22.66% return, which is significantly higher than TECH.AX's 13.34% return.


CURE.AX

1D
0.58%
1M
17.05%
6M
20.39%
YTD
22.66%
1Y
65.69%
3Y*
21.60%
5Y*
5.62%
10Y*

TECH.AX

1D
-0.93%
1M
-1.39%
6M
13.58%
YTD
13.34%
1Y
10.92%
3Y*
13.91%
5Y*
9.17%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CURE.AX vs. TECH.AX - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
CURE.AX
Global X S&P Biotech ETF
22.66%25.25%8.13%10.63%-22.98%-17.10%38.31%35.60%-13.56%
TECH.AX
Global X Morningstar Global Technology ETF
13.34%0.78%22.63%38.47%-29.11%22.40%34.82%39.22%-3.49%

Correlation

The correlation between CURE.AX and TECH.AX is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.43

Correlation (All Time)
Calculated using the full available price history since Nov 8, 2018

0.46

The correlation between CURE.AX and TECH.AX shifts across timeframes, from 0.26 (1 year) to 0.46 (all time), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Global X S&P Biotech ETF

Return for Risk

CURE.AX vs. TECH.AX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CURE.AX
CURE.AX Risk / Return Rank: 9090
Overall Rank
CURE.AX Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
CURE.AX Sortino Ratio Rank: 9090
Sortino Ratio Rank
CURE.AX Omega Ratio Rank: 8787
Omega Ratio Rank
CURE.AX Calmar Ratio Rank: 9595
Calmar Ratio Rank
CURE.AX Martin Ratio Rank: 8787
Martin Ratio Rank

TECH.AX
TECH.AX Risk / Return Rank: 1818
Overall Rank
TECH.AX Sharpe Ratio Rank: 2020
Sharpe Ratio Rank
TECH.AX Sortino Ratio Rank: 2020
Sortino Ratio Rank
TECH.AX Omega Ratio Rank: 2020
Omega Ratio Rank
TECH.AX Calmar Ratio Rank: 1515
Calmar Ratio Rank
TECH.AX Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CURE.AX vs. TECH.AX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X S&P Biotech ETF (CURE.AX) and Global X Morningstar Global Technology ETF (TECH.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CURE.AXTECH.AXDifference
Sharpe ratioReturn per unit of total volatility

+2.05

Sortino ratioReturn per unit of downside risk

+2.53

Omega ratioGain probability vs. loss probability

1.43

1.11

+0.31

Calmar ratioReturn relative to maximum drawdown

5.80

0.46

+5.34

Martin ratioReturn relative to average drawdown

14.61

0.99

+13.62

CURE.AX vs. TECH.AX - Sharpe Ratio Comparison

The current CURE.AX Sharpe Ratio is 2.62, which is higher than the TECH.AX Sharpe Ratio of 0.57. The chart below compares the historical Sharpe Ratios of CURE.AX and TECH.AX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CURE.AX vs. TECH.AX - Drawdown Comparison

The maximum CURE.AX drawdown since its inception was -59.81%, which is greater than TECH.AX's maximum drawdown of -31.78%. Use the drawdown chart below to compare losses from any high point for CURE.AX and TECH.AX.


Loading charts...

Drawdown Indicators


CURE.AXTECH.AXDifference

Max Drawdown

Largest peak-to-trough decline

-59.81%

-31.78%

-28.03%

Max Drawdown (1Y)

Largest decline over 1 year

-11.68%

-26.30%

+14.62%

Max Drawdown (3Y)

Largest decline over 3 years

-28.37%

-26.49%

-1.88%

Max Drawdown (5Y)

Largest decline over 5 years

-50.92%

-31.78%

-19.14%

Current Drawdown

Current decline from peak

-5.45%

-6.24%

+0.79%

Average Drawdown

Average peak-to-trough decline

-27.38%

-7.73%

-19.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.66%

12.27%

-7.61%

Volatility

CURE.AX vs. TECH.AX - Volatility Comparison

Global X S&P Biotech ETF (CURE.AX) has a higher volatility of 9.67% compared to Global X Morningstar Global Technology ETF (TECH.AX) at 6.78%. This indicates that CURE.AX's price experiences larger fluctuations and is considered to be riskier than TECH.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CURE.AXTECH.AXDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.67%

6.78%

+2.89%

Volatility (6M)

Calculated over the trailing 6-month period

21.01%

18.70%

+2.31%

Volatility (1Y)

Calculated over the trailing 1-year period

25.95%

21.13%

+4.82%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

30.91%

21.61%

+9.30%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

31.70%

21.03%

+10.67%

Dividends

CURE.AX vs. TECH.AX - Dividend Comparison

CURE.AX has not paid dividends to shareholders, while TECH.AX's dividend yield for the trailing twelve months is around 3.40%.


PositionTTM202520242023202220212020201920182017
CURE.AX
Global X S&P Biotech ETF
0.00%0.00%0.00%0.00%0.06%11.64%9.47%2.05%0.00%0.00%
TECH.AX
Global X Morningstar Global Technology ETF
3.40%11.08%6.23%0.50%4.95%13.65%7.67%7.75%6.07%0.84%

Frequently Asked Questions


CURE.AX and TECH.AX have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CURE.AX is categorized as Health & Biotech Equities, while TECH.AX is Technology Equities. CURE.AX tracks S&P Biotechnology Select Industry Index, while TECH.AX tracks Global X Morningstar Global Technology Index.

Portfolio Optimizer

Find the right allocation for CURE.AX and TECH.AX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer